The Body Compass GLP-1 Briefing

What's New in GLP-1 Treatment — A Quick Update

If you're using a GLP-1 medication, supporting someone who is, or simply keeping an eye on this fast-moving space, the last few months have brought some genuinely significant changes. Here's what's new, what it might mean for you, and what's still on the horizon.

NEW THIS YEAR A Wegovy Pill Is Now Available

In January 2026, an oral version of Wegovy (semaglutide) became available — the first oral GLP-1 medication approved specifically for weight management. It's also approved to help reduce cardiovascular risk in people who already have heart disease. For some people, the idea of a daily tablet rather than a weekly injection is genuinely appealing. If this is something you'd like to explore, it's worth raising with your prescriber — oral semaglutide does come with some timing considerations around food and water that are worth understanding before you switch.

NEW THIS YEAR A Higher-Dose Wegovy Injection

In March 2026, a higher-dose version of injectable Wegovy (7.2mg, sometimes called Wegovy HD) was approved. In clinical trials, this dose led to greater average weight loss than the standard 2.4mg dose — roughly 21% of body weight compared to around 17.5%, in people who stayed on treatment for the full study period. This isn't a dose everyone will need or be offered, and a higher dose isn't automatically the right choice for every person. But if your current dose has plateaued and you're due for a review, it may be worth asking your prescriber whether this is relevant for you.

NEW THIS YEAR Foundayo — A New Once-Daily Pill

In April 2026, a new oral medication called Foundayo (orforglipron) was approved for weight management. It's taken once a day and — unlike oral Wegovy — it doesn't come with restrictions around when you eat or drink relative to taking it. For many people, that's a meaningful difference in day-to-day convenience. Foundayo is a different type of molecule to the GLP-1 medications you may already know. If you've found the timing rules around other oral medications difficult to fit into your life, this is a conversation worth having with your prescriber.

ON THE HORIZON Mounjaro and Heart Health — A Decision Is Coming

Mounjaro (tirzepatide) is currently being reviewed for a new use: reducing the risk of serious cardiovascular events — heart attack, stroke, and cardiovascular death — in people with type 2 diabetes. A decision from regulators is expected, though no date has been confirmed. If you're taking Mounjaro for diabetes and also have cardiovascular risk factors, this is worth keeping an eye on. It won't change anything about your current prescription immediately, but it may shape future conversations with your care team.

ON THE HORIZON CagriSema — A New Combination Medication

A new medication called CagriSema, which combines semaglutide with a second hormone-based medication (cagrilintide), is currently awaiting a regulatory decision. In trials, people taking CagriSema lost an average of around 23% of their body weight. CagriSema isn't available yet, and there's no confirmed timeline for when a decision will be made. We'll keep you updated as this develops — but it's a good example of how quickly this field continues to evolve.

STILL IN TRIALS Retatrutide — The One Everyone's Watching

You may have seen retatrutide mentioned online — it's a medication still in clinical trials, not yet approved for prescription use anywhere. Recent trial results have generated a lot of attention because of the scale of weight loss seen in participants. It's important to know that retatrutide is not currently available as an approved prescription medication. Any product sold online claiming to be retatrutide has not been through the safety and quality checks that approved medications undergo. If you've seen this mentioned and you're curious, that's completely understandable — but please don't seek this out through unregulated sources. We'll let you know if and when this changes.

What This Means for You

None of this means you need to do anything right now. Your current treatment plan was chosen for good reasons, and new approvals don't automatically mean a new medication is right for you. What it does mean is that the landscape keeps shifting — and that's exactly why staying informed matters. A prescription is not the same thing as a plan, and part of having a plan is knowing what's changing around you, even if nothing changes for you personally.

• If you're curious about any of the above, the right place to start is a conversation with your prescriber at your next review — not a switch made on your own.
• If something here feels relevant to a plateau or side effect you've been experiencing, mention it. New options sometimes open up conversations that weren't possible before.
• If you're just here to stay informed, that's enough. You don't need to act on everything you read — you just need to know it's there.

A Note on Where This Information Comes From

This update draws on publicly available regulatory announcements and published clinical trial data current as of June 2026. It's provided for general information and does not replace advice from your prescriber, who knows your individual health history and circumstances.

As always, thank you for being part of this community. We'll keep watching this space — and we'll keep telling you what we see, plainly and without the hype.

With you on the journey,
The Body Compass Team

Body Compass · bodycompass.store · support@bodycompass.store